Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2020-10-10 Capital/Financing Update
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find attached outcome of Board meeting held on 10th October, 2020
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board Meeting held on October 10, 2020. The key subject is the approval of a preferential issue of fully convertible warrants to promoter group entities, including details such as the number of warrants, price, and terms of conversion. It also mentions an upcoming Extraordinary General Meeting for member approval of the preferential issue. The document includes detailed disclosures as required under SEBI regulations about the preferential allotment, names of investors, number of securities, and pricing. This is a clear update on capital raising activity and changes in the company's capital structure through a preferential allotment of warrants. It is not a full financial report, earnings release, or management discussion, but a regulatory announcement about financing activity. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2020-10-10 English
Board Meeting — Fund Raising
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about a scheduled Board Meeting of Morepen Laboratories Limited. The purpose of the meeting is to consider and approve proposals for raising funds through various modes such as public offer, right issue, preferential issue, or convertible instruments. The document references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which pertains to disclosures about board meetings. The document is short (1670 characters) and is an announcement of an upcoming board meeting focused on capital raising, not the actual report or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to fundraising activities and capital structure changes.
2020-10-07 English
MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/10/2020 ,inter alia, to consider and approve proposal for raising ....
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about a scheduled Board Meeting of Morepen Laboratories Limited. The purpose of the meeting is to consider and approve proposals for raising funds through various modes such as public offer, right issue, preferential issue, or convertible instruments. This is a notification about an upcoming board meeting focused on capital raising activities. It is not a full report, financial statement, or detailed presentation but an announcement of a board meeting with a specific agenda related to financing. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is short and does not contain financial data or detailed analysis, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing or Report Publication Announcement since it contains substantive information about the board meeting agenda rather than just a notice of report availability.
2020-10-07 English
Defaults on Payment of Interest/Principal
Regulatory Filings Classification · 95% confidence The document is a quarterly disclosure regarding the status of defaults on payment of interest/repayment of principal amount on loans from banks/financial institutions and unlisted debt securities. It references a SEBI circular dated November 21, 2019, and provides specific financial data as of September 30, 2020. The content is a regulatory compliance disclosure about loan defaults and financial indebtedness, not a full financial report or earnings release. The document length is short (2959 characters) and it is a formal regulatory announcement. This fits best under Regulatory Filings (RNS) as it is a compliance disclosure and does not contain comprehensive financial statements or detailed analysis typical of Interim Reports or Annual Reports.
2020-10-07 English
Morepen Laboratories Limited has informed BSE about the Loss of Share Certificates of the Company
Regulatory Filings Classification · 95% confidence The document is a series of letters addressed to stock exchanges (National Stock Exchange of India Ltd. and Bombay Stock Exchange Limited) reporting the loss of share certificates by shareholders and the request for issuance of duplicate share certificates. It references Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate loss and related disclosures. The content is about notifying the stock exchanges of these events, not about financial results, management changes, or other report types. The document is not a financial report, earnings release, or management discussion. It is a regulatory notification related to share certificates. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-10-07 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (National Stock Exchange of India Ltd. and Bombay Stock Exchange Limited) regarding the loss of share certificates by shareholders and the request for issuance of duplicate share certificates. It references Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to reporting such events. The content is a notification or intimation about the loss of share certificates rather than a financial report, management discussion, or any other detailed corporate filing. It does not contain financial data, earnings, governance details, or meeting materials. It is a regulatory announcement informing the exchanges and public about the loss of share certificates and related administrative actions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-10-07 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.